## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Single Technology Appraisal (STA)**

## Phentermine with topiramate for the treatment of obesity and overweight

## Matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Manufacturers/sponsors	General
Vivus (phentermine with topiramate)	Allied Health Professionals Federation
	Board of Community Health Councils in
Patient/carer groups	Wales
Action Heart     Africa Trust	British Cardiovascular Industry     Association
Afiya Trust     Post	Association
Beat     Black Health Agency	<ul><li>British National Formulary</li><li>Care Quality Commission</li></ul>
<ul><li>Black Health Agency</li><li>Blood Pressure Association</li></ul>	<ul><li>Care Quality Commission</li><li>Commissioning Support Appraisals</li></ul>
British Cardiac Patients Association	Services
Counsel and Care	Department of Health, Social Services
Diabetes Research & Wellness	and Public Safety for Northern Ireland
Foundation	Diabetes UK Cymru
Diabetes UK	Healthcare Improvement Scotland
Equalities National Council	<ul> <li>Medicines and Healthcare Products</li> </ul>
Healthier Weight Centres	Regulatory Agency
Heart Care Partnership UK	National Association of Primary Care
HEART UK	National Pharmacy Association
Insulin Dependent Diabetes Trust	NHS Alliance
Muslim Council of Britain	NHS Commercial Medicines Unit
Muslim Health Network	NHS Confederation     NHIS Trust
Network of Sikh Organisations UK	<ul><li>Public Health Wales NHS Trust</li><li>Scottish Medicines Consortium</li></ul>
National Obesity Forum     South Asian Health Foundation	Scottish Medicines Consortium
South Asian Health Foundation     Specialized Healthcare Alliance	Comparator manufacturers
<ul><li>Specialised Healthcare Alliance</li><li>Surya Foundation</li></ul>	GlaxoSmithKline (orlistat)
Weight Concern	Roche Products (Orlistat)
• Weight Concern	Teva UK (orlistat)
Professional groups	, ,
Association for the Study of Obesity	Relevant research groups
Association of British Clinical	British Society for Cardiovascular
Diabetologists	Research (BCS affiliated)
Association of Diabetes Specialist	Cardiovascular Diseases Specialist     Library
Nurses	<ul><li>Library</li><li>Cochrane Heart Group</li></ul>
British Association for Nursing in  Cardian Care	Cochrane Peripheral Vascular Disease
Cardiac Care	Group
British Association for Services to the	

National Institute for Health and Clinical Excellence

Matrix for the single technology appraisal of phentermine with topiramate for the treatment obesity and overweight

Issue date: September 2012

Consultees	Commentators (no right to submit or appeal)
	appeary
Elderly British Cardiovascular Intervention Society British Cardiovascular Society British Dietetic Association British Geriatric Society British Heart Foundation British Hypertension Society British Hypertension Society British Nutrition Foundation Diabetes Monitoring Forum Dieticians in Obesity Management Faculty of Public Health Medicine National Centre for Eating Disorders National Heart Forum UK Primary Care Cardiovascular Society Primary Care Diabetes UK Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology Society for Cardiological Science & Technology Society for Vascular Technology Society for Vascular Nurses The Nutrition Society The Obesity Management Association United Kingdom Clinical Pharmacy Association Vascular Society  Others Arden PCT Cluster Cwm Taf Health Board Department of Health Welsh Government	Cochrane Public Health Group CORDA MRC Clinical Trials Unit National Institute for Health Research Research Institute for the Care of Older People Wellcome Trust  Evidence Review Group National Institute for Health Research Health Technology Assessment Programme School of Health and Related Research Sheffield (ScHARR)  Associated Guideline Groups National Clinical Guidelines Centre  Associated Public Health Groups None

## PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence Matrix for the single technology appraisal of phentermine with topiramate for the treatment obesity and overweight

Issue date: September 2012

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### **Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute

National Institute for Health and Clinical Excellence Matrix for the single technology appraisal of phentermine with topiramate for the treatment obesity and overweight

Issue date: September 2012

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.